The 340B-program landscape has changed dramatically. For the 340B program’s first 28 years after its 1992 inception, the basic list of Best Practices for eligible entities remained largely unchanged — aside from the dramatically-increased importance of using specialized software. But since the June, 2020 introduction of 340B ESP — which has led to an avalanche … Read More
Manufacturers Accelerate Pace And Severity Of 340B Drug Pricing Restrictions
There’s an old saying that it’s better to be rich and guilty than poor and innocent. It’s a sad truth that accurately reflects the current state of 340B manufacturer restrictions, particularly in the wake of the January 30, 2023 decision by the U.S. Court of Appeals for the Third Circuit — which was largely in … Read More
Brick Walls: Dealing With 340B Manufacturer Restrictions.
A ProxsysRx Team Member Speaks Out. I joined ProxsysRx in early 2021, and I’ve been devoted to 340B program management full-time since early 2022. I’m no stranger to heavily regulated programs. Nearly my whole professional career has been in some aspect of public health — preclinical, clinical and now post-clinical. I’m currently fully devoted to … Read More
Seven Steps For Overcoming 340B ESP and Other Manufacturer Restrictions on 340B Pricing
ProxsysRx’s process for recovering lost 340B savings and revenue As we’ve noted in multiple earlier blog posts, 340B ESP is nothing short of a blatant, lawless tactic used by scores of drug manufacturers to disallow the discounts they are legally obligated to offer eligible entities. At the same time, a number of additional manufacturers are … Read More
Specialized Software Can Only Do So Much For 340B Programs
Why specialized software is essential for successful 340B programs As we’ve mentioned in several previous posts, many hospitals taking full advantage of 340B programs’ discounts save millions of dollars a year on prescription costs. However, 340B programs cover thousands of discounted drugs, and, for most eligible entities, thousands — if not tens of thousands — … Read More
Avoid These Six Common Errors When Reporting 340B-Eligible Prescriptions Through 340B ESP
As we noted in a previous post, 340B ESP is nothing less than a brazen and (in our opinion) unlawful ploy by the drug manufacturers to evade the discounts they are legally obligated to offer eligible entities — by placing extraordinary, and unnecessary, reporting burdens on hospitals submitting claims for 340B savings. That said, until … Read More
340B ESP. Why It’s Wrong, And How Hospitals Can Deal With It.
(NOTE: Over the years, we’ve served dozens of non-profit hospitals. We’ve seen the profound impact the 340B program has had in supporting their missions of serving the most vulnerable members of their communities. That said, we apologize, in advance, for the stridency of our tone on this page — but not for our sense of … Read More
How Drug Manufacturer Restrictions And PBMs Undermine Hospitals’ 340B Savings And Outpatient-Pharmacy Margins
If you’re an eligible hospital with an existing 340B program, you know that your wholly-owned outpatient pharmacy is required to buy non-340B medications at Wholesale Acquisition Cost (WAC) — unless you’ve put it in an LLC, and registered it as a child site, or you’re a Critical Access Hospital, and exempt from the requirement. You’ve … Read More
340B Best Practices You Need To Know
If your hospital is 340B-eligible, you may be missing-out on millions of dollars in prescription reimbursements. Savings and revenue which, for some hospitals served by ProxsysRx, actually make the difference between solvency and closure. Any list of Best Practices for running a 340B program starts with maintaining compliance. Tips for maintaining 340B Program Compliance The … Read More
What is 340B Double-Dipping, and How Can You Avoid It?
The 340B drug pricing program allows eligible providers to replenish prescriptions to eligible patients at significantly reduced pricing, and bill normal market rates for those prescriptions —helping the entities fill revenue gaps that are inherent to their business models. That said, the program does not allow eligible providers to take advantage of 340B discounts and … Read More